TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1037254

Group type: EXPERIMENTAL
Intervention: 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride (DL 150 IT) at 50 mug/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hydralazine at 250 mug/kg
Number of subjects: 5
Study: 28983557

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 2636
Study: 27662016

Group type: EXPERIMENTAL
Intervention: Tacrolimus/sirolimus
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cyclosporine/methotrexate
Number of subjects: 209
Study: 24744152

Group type: EXPERIMENTAL
Intervention: Short-interval lower-dose (SILD) intravenous cyclophosphamide (CYC) - 12 fortnightly pulses at 400 mg followed by 6 monthly pulses
Number of subjects: 225

Group type: COMPARATOR
Intervention: High-dose (HD) intravenous cyclophosphamide (CYC) - 6 monthly pulses followed by two quarterly pulses at 0.5-1.0 g/m(2)
Number of subjects: 225
Study: 22113951

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - long-term group
Number of subjects: 4550

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - cross-over group
Number of subjects: 4550

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - both groups
Number of subjects: 4550
Study: 19917652

Group type: EXPERIMENTAL
Intervention: Community health worker assessments and referrals for sick newborns
Number of subjects: 10006

Group type: EXPERIMENTAL
Intervention: Assessment by CHWs before death
Number of subjects: 10006
Study: 19134277

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 849

Group type: COMPARATOR
Intervention: On-pump CABG (CCAB)
Number of subjects: 849
Study: 15941900

Group type: EXPERIMENTAL
Intervention: Protein supplement (42 g protein, 24 g carbohydrate, 2 g fat)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carbohydrate supplement (70 g carbohydrate)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Protein supplement
Number of subjects: 51
Study: 14571155

Group type: EXPERIMENTAL
Intervention: Patient educational compliance enhancing programme (CP)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Overall adherence (measured by questioning, measurable serum levels, appointments kept, composite index)
Number of subjects: 1031
Study: 10739728

Group type: EXPERIMENTAL
Intervention: Intense insulin treatment
Number of subjects: 620

Group type: COMPARATOR
Intervention: Standard antidiabetic therapy
Number of subjects: 620
Study: 8640038

Group type: EXPERIMENTAL
Intervention: G985 mutation in medium-chain acyl-CoA dehydrogenase gene
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Infants dead from sudden infant death syndrome
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Medium-chain acyl-CoA dehydrogenase deficiency incidence
Number of subjects: 2000
Study: 1720217

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Phentolamine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Trimethaphan camsilate
Number of subjects: 25
Study: 6131148

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg intravenously)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diazepam (10 mg intravenously)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 78
Study: 31202919

Group type: EXPERIMENTAL
Intervention: Calorie summation condition (access to automatically updating calorie information)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No calorie summation condition (no access to automatically updating calorie information)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie summation condition
Number of subjects: 0
Study: 29754649

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist specialist‐delivered telehealth intervention
Number of subjects: 428

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 428
Study: 26702926

Group type: EXPERIMENTAL
Intervention: Raltegravir plus darunavir/ritonavir
Number of subjects: 805

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine plus darunavir/ritonavir
Number of subjects: 805
Study: 25224019

Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion/chorion membrane allograft and multilayer compression therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Multilayer compression therapy alone
Number of subjects: 84
Study: 22763903

Group type: EXPERIMENTAL
Intervention: TAP block (20 mL 0.5% ropivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo blocks
Number of subjects: 80
Study: 20231645

Group type: EXPERIMENTAL
Intervention: Standard informed consent with detailed informational aids
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard informed consent without detailed informational aids (Control)
Number of subjects: 34
Study: 17911647

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cure from VL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune responses in PKDL patients
Number of subjects: 0
Study: 15642816

Group type: EXPERIMENTAL
Intervention: Surgery for subfoveal choroidal neovascularization
Number of subjects: 225

Group type: COMPARATOR
Intervention: Observation for subfoveal choroidal neovascularization
Number of subjects: 225
Study: 12364969

Group type: EXPERIMENTAL
Intervention: Anal submucosal injection (ASI) of amikacin 400 mg daily for ten times
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular injection (IM) of amikacin 400 mg daily for ten times
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ASI group
Number of subjects: 50

Group type: COMPARATOR
Intervention: IM group
Number of subjects: 50
Study: 9989373

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7584917

Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide‐5‐mononitrate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide‐5‐mononitrate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate
Number of subjects: 141

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 141
Study: 2142577

Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/30)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biphasic desogestrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monophasic levonorgestrel (150/30)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/30) and biphasic desogestrel
Number of subjects: 0
Study: 498765

Group type: EXPERIMENTAL
Intervention: 100 mg tetraethylthiuramdisulfide (Antabuse) two to four times daily for 4-10 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Side effects of Antabuse treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nickel levels during treatment
Number of subjects: 11
Study: 30845329

Group type: EXPERIMENTAL
Intervention: Vi‐TCV vaccine
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 20000
Study: 28483503

Group type: COMPARATOR
Intervention: REI‐ObGyn
Number of subjects: 630

Group type: COMPARATOR
Intervention: ObGyn
Number of subjects: 630

Group type: COMPARATOR
Intervention: Lifestyle changes recommendation
Number of subjects: 630
Study: 25636048

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 191
Study: 23460234

Group type: EXPERIMENTAL
Intervention: Milk fortified with 600 IU (15 μg) of vitamin D per day for 12 weeks
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Milk fortified with 1,000 IU (25 μg) of vitamin D per day for 12 weeks
Number of subjects: 713

Group type: COMPARATOR
Intervention: Unfortified milk (control group) 200 ml per day for 12 weeks
Number of subjects: 713
Study: 21280197

Group type: EXPERIMENTAL
Intervention: MTX 1 g/m² in 24 hr with intrathecal injection
Number of subjects: 352

Group type: COMPARATOR
Intervention: MTX 3 g/m² in 3 hr without intrathecal
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Courses with vinblastine
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 352
Study: 19843421

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: No antibiotics
Number of subjects: 807

Group type: COMPARATOR
Intervention: Information leaflet
Number of subjects: 807
Study: 16776933

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 92

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 92
Study: 14647254

Group type: EXPERIMENTAL
Intervention: Donor vaccination on day -20, recipient vaccination on days -1, +50, and +365 (D(-20)R(-1,50,365))
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Recipient vaccination on days -1, +50, and +365 (D(N)R(-1,50,365))
Number of subjects: 85

Group type: COMPARATOR
Intervention: Recipient vaccination on day +365 (D(N)R(365))
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Recipient immunization on days -1 and 50
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Donor vaccination on day -20
Number of subjects: 85
Study: 11575522

Group type: EXPERIMENTAL
Intervention: Modified Foley catheter (hole-end catheter)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 72
Study: 9754589

Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 9
Study: 7836943

Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal low‐density lipoprotein/fibrinogen precipitation (HELP)
Number of subjects: 0
Study: 3286287

Group type: EXPERIMENTAL
Intervention: Sperm incubated in medium containing 20% serum with antisperm activity (Test)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No antisperm activity (Control)
Number of subjects: 17
Study: 31542640

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens (specific regimens not detailed)
Number of subjects: 1654
Study: 31065133

Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (Control)
Number of subjects: 60
Study: 26872450

Group type: EXPERIMENTAL
Intervention: Faecal Immunochemical Test (FIT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Faecal Occult Blood Test (FOBT)
Number of subjects: 200
Study: 24821891

Group type: EXPERIMENTAL
Intervention: Interactive multimedia computer program (IMCP) tailored to colorectal cancer screening
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Nontailored informational program (control)
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Interactive multimedia computer program (IMCP)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: IMCP vs Control
Number of subjects: 1164
Study: 23185280

Group type: EXPERIMENTAL
Intervention: Intravenous amantadine (400 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amantadine tablet (open-label follow-up)
Number of subjects: 10
Study: 21302486

Group type: EXPERIMENTAL
Intervention: Fengshikang (FSK) combined with glucocorticoid therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methotrexate (MTX) with glucocorticoid therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal control group (healthy subjects)
Number of subjects: 38
Study: 17351951

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with epirubicin, paclitaxel, and cyclophosphamide plus darbepoetin alpha
Number of subjects: 101
Study: 15466946

Group type: EXPERIMENTAL
Intervention: Oats (60 g oatmeal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) plus Vitamin C (500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of oats and vitamins
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10837840

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (tea and coffee with 37.5 mg and 75 mg caffeine in tea, 75 mg and 150 mg caffeine in coffee)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (with varying caffeine levels: 0, 25, 50, 100, and 200 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 32

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 32
Study: 9205202

Group type: EXPERIMENTAL
Intervention: Combined irradiation and operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation alone
Number of subjects: 0
Study: 8403296

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA) infusion
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with appropriate supplemental measures
Number of subjects: 2885
Study: 3096767

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 3131404

Group type: EXPERIMENTAL
Intervention: gallopamil (10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: cromolyn sodium (20 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: control
Number of subjects: 9
Study: 31237053

Group type: EXPERIMENTAL
Intervention: 10 hours or longer per day working hours among males with the highest household income
Number of subjects: 11602

Group type: COMPARATOR
Intervention: Low household income males
Number of subjects: 11602
Study: 28370389

Group type: EXPERIMENTAL
Intervention: VSX-objective refraction (optimised using visual Strehl ratio)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subjective refraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VSX-objective refraction
Number of subjects: 20
Study: 26464454

Group type: EXPERIMENTAL
Intervention: THC (Δ9-tetrahydrocannabinol) administered intravenously
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 23390362

Group type: EXPERIMENTAL
Intervention: Exercise intervention (6-month, twice weekly)
Number of subjects: 44
Study: 21472530

Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment using Visual Analogic Scale (VAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for interleukin‐6 (IL6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for interleukin‐1 (IL1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for tumor necrosis factor‐alpha (TNF‐alpha)
Number of subjects: 0
Study: 18058656

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 98
Study: 16551312

Group type: EXPERIMENTAL
Intervention: Provider reminder
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Provider reminder plus patient education
Number of subjects: 311

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 311
Study: 15273108

Group type: EXPERIMENTAL
Intervention: Antibacterial cleaning products (0.2% triclosan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonantibacterial cleaning products
Number of subjects: 0
Study: 11174445

Group type: EXPERIMENTAL
Intervention: MPEG-1
Number of subjects: 20

Group type: COMPARATOR
Intervention: sVHS
Number of subjects: 20
Study: 9640082

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-D-glucosaminidase (NAG) urine activity in patients with chronic renal failure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients with massive proteinuria (> 1.5 g/24 h)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients with moderate proteinuria
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients without 24 hour proteinuria or non-significant proteinuria
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAG values above and below 280 nmol/mg of creatinine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAG values higher than 280 nmol/mg of creatinine
Number of subjects: 63
Study: 8278671

Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reinforcement program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Exercise-only control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study: 3552920

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Splenorenal shunt
Number of subjects: 112
Study: 29542334

Group type: EXPERIMENTAL
Intervention: Non-biologic treatment plans (glucocorticoids alone and methotrexate)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Biologic treatment plans (interleukin-1 blockade and interleukin-6 blockade)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System measures
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Other parent-/patient-reported outcomes
Number of subjects: 200
Study: 28599712

Group type: EXPERIMENTAL
Intervention: 0.65-g alcohol dose/kg body weight
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 26534969

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg for 90 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 41
Study: 23109251

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study: 21074021

Group type: EXPERIMENTAL
Intervention: Carraguard
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 18556101

Group type: EXPERIMENTAL
Intervention: Web-based health education intervention
Number of subjects: 1892
Study: 16458213

Group type: EXPERIMENTAL
Intervention: Guidewire-assisted radial artery cannulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct radial artery cannulation
Number of subjects: 100
Study: 14613739

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (General Health Questionnaire score >/=5)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1130
Study: 10639542

Group type: EXPERIMENTAL
Intervention: Routine medical testing (electrocardiography, complete blood count, serum levels of electrolytes, urea nitrogen, creatinine, glucose) before cataract surgery
Number of subjects: 18189

Group type: COMPARATOR
Intervention: No routine medical testing before cataract surgery
Number of subjects: 18189

Group type: EXPERIMENTAL
Intervention: Routine medical testing before cataract surgery
Number of subjects: 18189
Study: 9366542

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 110

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) preparations
Number of subjects: 110
Study: 1583824

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Heparin (H)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Reduction of ST-segment elevation by 50% after 2 hours of treatment
Number of subjects: 532
Study: 4041324

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% amethocaine
Number of subjects: 20
Study: 30570839

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg after a high-fat meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Brigatinib 180 mg after fasting
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment-emergent adverse events under fasted conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events under fed conditions
Number of subjects: 24
Study: 30518514

Group type: EXPERIMENTAL
Intervention: Thinking Well intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SlowMo therapy (new intervention)
Number of subjects: 0
Study: 26936074

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24550332

Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)‐boosted Elvitegravir (EVG/co) (150/150 mg) administered once daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls (n = 10)
Number of subjects: 20
Study: 21727201

Group type: EXPERIMENTAL
Intervention: Plasma MMP-2 at 0 and 12 h
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TIMP-1 and TIMP-2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MMP-8, MMP-9 and MPO
Number of subjects: 58
Study: 19953610

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.75% ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ropivacaine group
Number of subjects: 100
Study: 17179200

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (50 microg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study: 14693980

Group type: EXPERIMENTAL
Intervention: SU plus pioglitazone
Number of subjects: 639

Group type: COMPARATOR
Intervention: SU plus metformin
Number of subjects: 639
Study: 11576740

Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs about work
Number of subjects: 78

Group type: COMPARATOR
Intervention: Initial evaluation measurements
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs
Number of subjects: 78